hackint0sh/temp-data huggingface dataset:
protocolSection identificationModule nctId: NCT06355570, orgStudyIdInfo id: 331314, secondaryIdInfos id: RFPR2324_29, type: OTHER_GRANT, domain: Imperial Health Charity, secondaryIdInfos id: 24/YH/0011, type: OTHER, domain: UK Health Research Authority (Research Ethics Committee), briefTitle: Delirium After Cardiac Surgery in Intensive Care Units, acronym: DaCsi-ICU, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-20, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-03-20, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-11, sponsorCollaboratorsModule leadSponsor name: Imperial College Healthcare NHS Trust, class: OTHER, descriptionModule briefSummary: STUDY SUMMARYSTUDY DESIGN The study will be conducted over twelve months in the Cardiac Intensive Care Unit (ICU) at Hammersmith Hospital, Imperial College Healthcare NHS Trust (ICHT). This study is a mixed methods research design that includes the collection of data through qualitative interviews, quality-of-life questionnaires and patients' medical records.AIMS* Determine the incidence of ICU delirium in ICHT following cardiac surgery* Explore the compliance of outcome measures that diagnose ICU delirium* Implement a family-focused sensory stimulation programme in the ICU* Evaluate its useability and potential impact on patients, families and ICU staffSTUDY POPULATION 30 study participants (12 patients, 12 family members/friends and 6 ICU nurses)ELIGIBILITY Study eligibility criteria are specific for each care group (patients, family members/friends and ICU nurses).DURATION 12 months at Hammersmith Hospital, ICHT, conditionsModule conditions: Intensive Care Unit Delirium, conditions: Cardiac Surgery, conditions: Post Operative Delirium, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: NA, interventionModel: SINGLE_GROUP, interventionModelDescription: 12-patient participants will be submitted to the study intervention., primaryPurpose: BASIC_SCIENCE, maskingInfo masking: NONE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Personal Pictures, interventions name: Family Videos, interventions name: Family Videos - Intervention as required, outcomesModule primaryOutcomes measure: Feasibility of implementing the study intervention, secondaryOutcomes measure: Practicalities of introducing the study intervention, secondaryOutcomes measure: Acceptability of implementing the study intervention, secondaryOutcomes measure: Short-term delirium outcomes post-ICU discharge, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Imperial College Healthcare NHS Trust, status: RECRUITING, city: London, zip: W12 0HS, country: United Kingdom, contacts name: Maria Reguenga, BSN, role: CONTACT, phone: +442033131703, email: maria.reguenga@nhs.net, contacts name: Sanooj Soni, PhD, role: CONTACT, phone: 07714329708, email: sanooj.soni@nhs.net, geoPoint lat: 51.50853, lon: -0.12574, hasResults: False
protocolSection identificationModule nctId: NCT06355557, orgStudyIdInfo id: DSRB 2023/00640, briefTitle: Human vs Machine: a RCT Comparing Traditional In-person Instruction, AI Versus VR for Learning Basic CCE, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-04-04, primaryCompletionDateStruct date: 2024-12-31, completionDateStruct date: 2025-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Tan Tock Seng Hospital, class: OTHER, descriptionModule briefSummary: The aim of the study is to investigate if hands-on training for basic CCE with virtual reality simulators or guided by artificial intelligence is non-inferior to training by an experienced instructor., conditionsModule conditions: Ultrasound, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, interventionModelDescription: 3-arm prospective randomised controlled trial., primaryPurpose: OTHER, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 66, type: ESTIMATED, armsInterventionsModule interventions name: AI enabled ultrasound system for self-directed learning, interventions name: Simulator for self-directed learning, interventions name: traditional with human instructors, outcomesModule primaryOutcomes measure: Improvement in image acquisition and structure identification at the end of 3 months., eligibilityModule sex: ALL, minimumAge: 21 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Tan Tock Seng Hospital, status: RECRUITING, city: Singapore, zip: 319581, country: Singapore, contacts name: Yie H Lau, role: CONTACT, phone: 6563577771, email: yie_hui_lau@ttsh.com.sg, contacts name: Yie H Lau, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 1.28967, lon: 103.85007, hasResults: False
protocolSection identificationModule nctId: NCT06355531, orgStudyIdInfo id: FNP223-CT-2301, briefTitle: A Study to Assess the Efficacy, Safety, and Pharmacokinetics of FNP-223 to Slow Progression of Progressive Supranuclear Palsy (PSP), statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-11, completionDateStruct date: 2026-11, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Ferrer Internacional S.A., class: INDUSTRY, descriptionModule briefSummary: PROSPER trial is a trial to assess the efficacy of FNP-223 in slowing disease progression in participants with PSP as measured by the PSP Rating Scale (PSPRS) over 52 weeks and to assess the safety and tolerability of FNP-223 for 52 weeks in participants with PSP., conditionsModule conditions: Progressive Supranuclear Palsy, designModule studyType: INTERVENTIONAL, phases: PHASE2, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 220, type: ESTIMATED, armsInterventionsModule interventions name: FNP-223, interventions name: Placebo, outcomesModule primaryOutcomes measure: Change From Baseline to Week 52 in the PSPRS Outcome, primaryOutcomes measure: Number of Participants Experiencing Treatment-emergent Adverse Events (TEAEs), primaryOutcomes measure: Number of Participants Experiencing Serious Adverse Events (SAEs), secondaryOutcomes measure: Change From Baseline to Week 52 in Clinical Global Impression of Severity Scale (CGI-S), secondaryOutcomes measure: Change From Baseline to Week 52 Participant Global Impression of Severity Scale (PGI-S), secondaryOutcomes measure: Change From Baseline to Week 52 in Caregiver Global Impression of Severity Scale (CaGI-S), secondaryOutcomes measure: Slope of Decline in PSPRS, secondaryOutcomes measure: Change From Baseline to Week 52 in Individual Subitems of PSPRS, secondaryOutcomes measure: Change From Baseline to Week 52 in Schwab and England Activities of Daily Living Scale, secondaryOutcomes measure: Change From Baseline to Week 52 in PSP Clinical Deficits Scale (PSP-CDS), secondaryOutcomes measure: Change From Baseline to Week 52 in Montreal Cognitive Assessment (MoCA), secondaryOutcomes measure: Change From Baseline to Week 52 in PSP Quality of Life Scale (PSP-QoL), secondaryOutcomes measure: Pharmacokinetic characterization of FNP-223, eligibilityModule sex: ALL, minimumAge: 50 Years, maximumAge: 80 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06355518, orgStudyIdInfo id: INu-RC, briefTitle: Pre-operative Immuno-Nutrition in Radical Cystectomy, acronym: INu-RC, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-09, completionDateStruct date: 2026-09, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Fondazione IRCCS Policlinico San Matteo di Pavia, class: OTHER, collaborators name: IRCCS Ospedale San Raffaele, descriptionModule briefSummary: This study will evaluate the effect of preoperative oral immunonutrition on postoperative complications in patients undergoing radical cystectomy for bladder cancer. Patients receiving preoperative immunonutrition will be compared to controls receiving a standard high-calorie, high-protein oral nutritional supplement., conditionsModule conditions: Bladder Cancer, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 260, type: ESTIMATED, armsInterventionsModule interventions name: Immunonutrition, interventions name: Standard Oral Nutritional Supplement, outcomesModule primaryOutcomes measure: 30-day complications, secondaryOutcomes measure: 30-day severe complications, secondaryOutcomes measure: 90-day severe complications, secondaryOutcomes measure: 30-day and 90-day infectious complications, secondaryOutcomes measure: 30-day and 90-day occurrence of other medical conditions, secondaryOutcomes measure: Time to recovery of bowel function, secondaryOutcomes measure: Time to postoperative mobilization, secondaryOutcomes measure: Muscular strength modifications, secondaryOutcomes measure: Weight modifications, secondaryOutcomes measure: Biochemical nutritional indexes modifications, secondaryOutcomes measure: Need of blood transfusions, secondaryOutcomes measure: Length of stay, secondaryOutcomes measure: Readmission rate, secondaryOutcomes measure: 30-day and 90-day mortality, secondaryOutcomes measure: Compliance, secondaryOutcomes measure: Tolerability (gastrointestinal symptoms related to nutritional supplement), eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: IRCCS Ospedale San Raffaele, city: Milan, zip: 20132, country: Italy, contacts name: Bettiga Arianna, role: CONTACT, email: bettiga.arianna@hsr.it, contacts name: Marco Moschini, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.46427, lon: 9.18951, locations facility: Fondazione IRCCS Policlinico San Matteo, city: Pavia, zip: 27100, country: Italy, contacts name: Ferrari Alessandra, PharmD, role: CONTACT, phone: +390382503689, email: alessandra.ferrari@smatteo.pv.it, contacts name: Valentina Da Prat, MD, role: PRINCIPAL_INVESTIGATOR, geoPoint lat: 45.19205, lon: 9.15917, hasResults: False
protocolSection identificationModule nctId: NCT06355505, orgStudyIdInfo id: PREPS-21-0098, briefTitle: Process of Emergence and Implementation of Advanced Practice Nursing in France, acronym: PEIPA, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-01, primaryCompletionDateStruct date: 2028-01-01, completionDateStruct date: 2028-03-01, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Assistance Publique - Hôpitaux de Paris, class: OTHER, descriptionModule briefSummary: Longitudinal, observational research with a mixed quantitative (by questionnaires) and qualitative (by interviews and observations) approach, multidisciplinary, among Advanced Practice Nurses (APNs) already graduated and 3 consecutive classes of advanced practice students who will be followed annually during their implementation as APN until the last year of the study. The questionnaires will focus on APN scope of practice evolution, economical analysis and geographical distribution of APN. The ethnographical approach will assess APN settlements and relation with healthcare colleagues and patients., conditionsModule conditions: Nurse's Role, designModule studyType: OBSERVATIONAL, designInfo observationalModel: OTHER, timePerspective: PROSPECTIVE, enrollmentInfo count: 1600, type: ESTIMATED, armsInterventionsModule, outcomesModule primaryOutcomes measure: Factors influencing the effective implementation of advanced practice nursing in France in primary care and health facilities, secondaryOutcomes measure: Mapping of APNs in France with socio-demographic data, secondaryOutcomes measure: Definition by the APN of its role and missions, secondaryOutcomes measure: Implementation and dissemination of the APN practice in the territory according to the context of practice (community care, hospital), secondaryOutcomes measure: Identification of potential impact dimensions of Advanced Practice Nursing, eligibilityModule sex: ALL, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Beaujon hospital, status: RECRUITING, city: Clichy, zip: 92110, country: France, contacts name: Julie Devictor, PhD, role: CONTACT, phone: 06 64 71 26 75, email: julie.devictor@aphp.fr, contacts name: Anne Leclercq, PhD, role: CONTACT, phone: 0033 7 62 70 58 05, email: anne.leclercq2@aphp.fr, geoPoint lat: 48.90018, lon: 2.30952, hasResults: False
protocolSection identificationModule nctId: NCT06355492, orgStudyIdInfo id: 2090/10/30, briefTitle: Virtual Reality Distraction in Pediatric Patients., statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-06-01, primaryCompletionDateStruct date: 2025-06, completionDateStruct date: 2025-07, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Tanta University, class: OTHER, descriptionModule briefSummary: The aim of this study is to evaluate the effect of virtual reality distraction on pain and anxiety during infiltration anesthesia in pediatric patients., conditionsModule conditions: Virtual Reality, conditions: Distraction, conditions: Infiltration Anesthesia, conditions: Pediatric Patients, designModule studyType: INTERVENTIONAL, phases: PHASE4, designInfo allocation: RANDOMIZED, interventionModel: CROSSOVER, primaryPurpose: PREVENTION, maskingInfo masking: DOUBLE, whoMasked: PARTICIPANT, whoMasked: INVESTIGATOR, enrollmentInfo count: 150, type: ESTIMATED, armsInterventionsModule interventions name: Virtual reality goggles (VR ), interventions name: regular screen, outcomesModule primaryOutcomes measure: Assessment of pain during virtual reality distraction, eligibilityModule sex: ALL, minimumAge: 6 Years, maximumAge: 12 Years, stdAges: CHILD, contactsLocationsModule locations facility: Rokia Abdelrhman Saad Elfaramawy, city: Tanta, state: El-Gharbia, zip: 31527, country: Egypt, contacts name: Rokia A Elfaramawy, BDS, role: CONTACT, phone: 01069823221, email: Rokiaabdelrahman94@gmail.com, contacts name: Fatma A Elhendawy, Professor, role: SUB_INVESTIGATOR, contacts name: Nura I Abozena, Lecturer, role: SUB_INVESTIGATOR, geoPoint lat: 30.78847, lon: 31.00192, hasResults: False
protocolSection identificationModule nctId: NCT06355466, orgStudyIdInfo id: 51-112334, briefTitle: Tunneled Hemodialysis Catheters as Permanent Vascular Access: Evaluating One-year Patency Rate and Affecting Factors, statusModule overallStatus: COMPLETED, startDateStruct date: 2022-01-09, primaryCompletionDateStruct date: 2023-08-11, completionDateStruct date: 2023-08-28, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Golestan University of Medical sciences, class: OTHER, descriptionModule briefSummary: In this prospective cross-sectional study, patients with ESRD unfit for AVF/AVG were scheduled for a right or left trans-jugular tunneled catheter placement. All patients were asked about their catheters' function one year after its implantation and the presumed affecting factors on catheters' patency were evaluated., conditionsModule conditions: Vascular Access Devices, designModule studyType: OBSERVATIONAL, designInfo observationalModel: CASE_ONLY, timePerspective: PROSPECTIVE, enrollmentInfo count: 156, type: ACTUAL, outcomesModule primaryOutcomes measure: one year patency rate of hemodialysis catheters, secondaryOutcomes measure: one year patency rate of hemodialysis catheters in age subgroups, secondaryOutcomes measure: one year patency rate of hemodialysis catheters in diabetic patients, secondaryOutcomes measure: one year patency rate of hemodialysis catheters in hypertensive patients, secondaryOutcomes measure: one year patency rate of hemodialysis catheters in patients on antiplatelet drugs, secondaryOutcomes measure: one year patency rate of hemodialysis catheters in sex subgroups, eligibilityModule sex: ALL, stdAges: CHILD, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Golestan University of Medical Sciences, faculty of medicine, city: Gorgan, state: Golestan, zip: 4918936316, country: Iran, Islamic Republic of, geoPoint lat: 36.8427, lon: 54.44391, hasResults: False
protocolSection identificationModule nctId: NCT06355453, orgStudyIdInfo id: 2023-090-MIC-GES, briefTitle: Evaluation of the Goldcrest Patch Performance, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04-25, primaryCompletionDateStruct date: 2024-08-30, completionDateStruct date: 2024-12-31, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: GE Healthcare, class: INDUSTRY, descriptionModule briefSummary: The Novii Patch is an accessory to the Novii+ Pod that connects directly to the Novii+ Pod and contains the surface electrodes that attach to the abdomen.The primary objective is to collect Data on Skin Integrity and Patch Adhesion Quality From the Patch After 18 Hours of Wear. The secondary objective is to evaluate fetal monitoring on adult pregnant females greater than 32 weeks gestation and non-pregnant females to collect data on electrical fetal, maternal, and uterine activity., conditionsModule conditions: Fetal Monitoring, designModule studyType: OBSERVATIONAL, designInfo observationalModel: COHORT, timePerspective: PROSPECTIVE, enrollmentInfo count: 30, type: ESTIMATED, armsInterventionsModule interventions name: Goldcrest Patch and Three Patch Coupons, interventions name: Goldcrest Patch and Novii Patch, outcomesModule primaryOutcomes measure: Primary Objective, primaryOutcomes measure: Primary Objective, secondaryOutcomes measure: Secondary Objective, secondaryOutcomes measure: Secondary Objective, otherOutcomes measure: Incidence of Treatment-Emergent Adverse Events Objective, eligibilityModule sex: FEMALE, minimumAge: 22 Years, maximumAge: 70 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule, hasResults: False
protocolSection identificationModule nctId: NCT06355440, orgStudyIdInfo id: 2312288-16, briefTitle: Pilot Study of Financial Navigation Program for Improving Financial Toxicity Among Breast Cancer in China, statusModule overallStatus: RECRUITING, startDateStruct date: 2024-03-18, primaryCompletionDateStruct date: 2024-06-30, completionDateStruct date: 2024-06-30, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Fudan University, class: OTHER, descriptionModule briefSummary: The goal of this pilot study is to access the feasibility and impact of a financial navigation program on improving financial toxicity among patients with breast cancer in China.The main questions it aims to answer are:* Is the intervention feasible and acceptable among participants?* Does the intervention enhance participants' cost-related health literacy?* Does the intervention reduce participants' financial toxicity?Researchers will compare the financial navigation program with usual oncology care to preliminarily evaluate its effectiveness.Participants will receive comprehensive information support, including:* Strategies on patient-physician costs discussion* Skills for inquiring and tracking treatment-related costs* Basic knowledge about health insurance* Guidance on accessing and applying for financial assistance* Suggestions for returning to normal life and work* Strategies for holding a financial-related family meeting, conditionsModule conditions: Breast Neoplasm Female, conditions: Financial Toxicity, conditions: Financial Navigation, designModule studyType: INTERVENTIONAL, phases: NA, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: SUPPORTIVE_CARE, maskingInfo masking: SINGLE, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 24, type: ESTIMATED, armsInterventionsModule interventions name: Financial Navigation, interventions name: Usual Care, outcomesModule primaryOutcomes measure: Eligibility rate, primaryOutcomes measure: Consent rate, primaryOutcomes measure: Retention rate, primaryOutcomes measure: Adherence rate, primaryOutcomes measure: Patient-reported satisfaction, primaryOutcomes measure: Qualitative assessment of the intervention, secondaryOutcomes measure: Cost-related health literacy, secondaryOutcomes measure: Financial toxicity, secondaryOutcomes measure: Material domain of financial toxicity, secondaryOutcomes measure: Behavioral domain of financial toxicity, eligibilityModule sex: FEMALE, minimumAge: 18 Years, stdAges: ADULT, stdAges: OLDER_ADULT, contactsLocationsModule locations facility: Fudan University Shanghai Cancer Center, status: RECRUITING, city: Shanghai, state: Shanghai, zip: 200032, country: China, contacts name: Xiaoyi Yuan, Master, role: CONTACT, phone: (+86) 18918305439, email: 22211170009@m.fudan.edu.cn, geoPoint lat: 31.22222, lon: 121.45806, hasResults: False
protocolSection identificationModule nctId: NCT06355401, orgStudyIdInfo id: Soh-Med-24-03--06PD, briefTitle: Maintenance Hormonal Therapy and DLBCL, statusModule overallStatus: NOT_YET_RECRUITING, startDateStruct date: 2024-04, primaryCompletionDateStruct date: 2026-03, completionDateStruct date: 2029-03, studyFirstPostDateStruct date: 2024-04-09, lastUpdatePostDateStruct date: 2024-04-09, sponsorCollaboratorsModule leadSponsor name: Sohag University, class: OTHER, descriptionModule briefSummary: the study aims to detect the benefit of maintenance tamoxifen after achieving CR with conventional immuno-chemotherapy and/or radiotherapy in patients with DLDCL, conditionsModule conditions: Diffuse Large B Cell Lymphoma, designModule studyType: INTERVENTIONAL, phases: PHASE2, phases: PHASE3, designInfo allocation: RANDOMIZED, interventionModel: PARALLEL, primaryPurpose: TREATMENT, maskingInfo masking: DOUBLE, whoMasked: INVESTIGATOR, whoMasked: OUTCOMES_ASSESSOR, enrollmentInfo count: 100, type: ESTIMATED, armsInterventionsModule interventions name: Tamoxifen 20mg, outcomesModule primaryOutcomes measure: disease free survival, primaryOutcomes measure: overall survival, secondaryOutcomes measure: side effects, eligibilityModule sex: ALL, minimumAge: 18 Years, maximumAge: 75 Years, stdAges: ADULT, stdAges: OLDER_ADULT, hasResults: False